# Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)

> **NCT00162929** · PHASE1 · COMPLETED · sponsor: **Ontario Clinical Oncology Group (OCOG)** · enrollment: 5 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **BIOLOGICAL:** AdHer-2/neu transduced dendritic cells

## Key facts

- **NCT ID:** NCT00162929
- **Lead sponsor:** Ontario Clinical Oncology Group (OCOG)
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2009-07
- **Final completion:** 2012-05
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2012-06-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162929, "Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00162929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*